UnitedHealth Group (UNH) Stock Forecast & Price Target

UnitedHealth Group is supported by unmatched scale across medical benefits and a diversified Optum platform that spans PBM, outpatient care, and analytics, giving it broad exposure to the healthcare continuum and a durable competitive moat. The company’s 3Q26 adjusted EPS of $4.69 beat consensus on an 88.4% MLR, while full-year 2026 adjusted EPS guidance rose to at least $20.50, reinforcing confidence that execution remains strong and that 13–16% long-term earnings growth is still achievable. Its outlook is further strengthened by improving Medicare Advantage margins near the top of the 2–4% range, Medicaid trends that appear to be troughing, and OptumHealth’s durable outperformance, all of which support margin expansion and strong cash generation.

UnitedHealth Group is exposed to mounting fundamental pressure from Medicare Advantage utilization, commercial trend inflation, and regulatory uncertainty, all of which could erode margins and reduce earnings quality. The downside case assumes FY28 EPS comes in about 10% below the base case as the P/E multiple compresses to 15.0x, while 2026 is further affected by v28 risk-model changes, a year 3 phase-in, and an incremental ~50bps headwind from IDR within >11% cost trend growth. Beyond operating pressure, the company faces execution risk in medical cost forecasting and network contracting, reimbursement risk in government business, and continued DOJ and headline scrutiny, which could weigh on sentiment and valuation.